查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1881573

氣喘治療市場－全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、產品（吸入器、霧化器）、給藥途徑、地區和競爭格局分類，2020-2030年預測

Asthma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Product (Inhalers, Nebulizers), By Route of Administration, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球氣喘治療市場規模預計將從2024年的275.2億美元成長至2030年的343億美元，年複合成長率（CAGR）為3.74%。氣喘治療涵蓋一系列旨在控制和緩解氣喘症狀的藥物和治療方法。氣喘是一種慢性呼吸系統疾病，其特徵是氣道發炎和狹窄。市場成長的主要促進因素是全球氣喘盛行率的不斷上升，尤其是在城市化地區，以及人們對疾病管理意識的提高。

市場概覽
預測期 2026-2030
2024年市場規模 275.2億美元
2030年市場規模 343億美元
2025-2030年複合年成長率 3.74%
成長最快的細分市場 聯合療法
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球氣喘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（抗發炎藥、合併用藥、支氣管擴張劑）
    • 依產品分類（吸入器、霧化器）
    • 依給藥途徑（口服、吸入、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美氣喘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲氣喘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區氣喘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲氣喘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲氣喘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球氣喘治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Teva Pharmaceutical Industries Ltd.
  • GSK plc.
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca plc.
  • Boehringer Ingelheim International GmbH
  • Sanofi SA
  • Koninklijke Philips NV
  • Becton, Dickinson and Company
  • Sunovion Pharmaceuticals, Inc.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 22132

The Global Asthma Therapeutics Market will grow from USD 27.52 Billion in 2024 to USD 34.3 Billion by 2030 at a 3.74% CAGR. Asthma therapeutics encompass a range of pharmaceutical medications and treatment modalities designed to manage and alleviate the symptoms of asthma, a chronic respiratory condition characterized by airway inflammation and narrowing. The market's growth is primarily driven by the escalating global prevalence of asthma, particularly in urbanized regions, and the increasing awareness regarding disease management.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 27.52 Billion
Market Size 2030USD 34.3 Billion
CAGR 2025-20303.74%
Fastest Growing SegmentCombination Therapy
Largest MarketNorth America

Key Market Drivers

The increasing global asthma prevalence significantly propels the demand for therapeutics. A growing number of individuals worldwide are diagnosed with this chronic respiratory condition, necessitating long-term management and various treatment interventions. This expanding patient population inherently broadens the market for existing medications and drives the need for new therapeutic developments. Factors such as urbanization, increased exposure to environmental allergens, and lifestyle changes contribute to the rising incidence of asthma across diverse demographics.

Key Market Challenges

The high cost associated with advanced biologic therapies represents a significant challenging factor for the global asthma therapeutics market. This elevated pricing directly impacts patient access, particularly in diverse healthcare systems where reimbursement policies or individual financial capacities may be restrictive. Consequently, a substantial portion of the patient population requiring these advanced treatments may face barriers to obtaining them, thereby limiting the overall market penetration and expansion of these innovative therapies.

Key Market Trends

This trend transforms asthma management via real-time data and enhanced medication adherence. Digital health platforms and smart inhalers, with sensors, monitor usage and technique, directly improving treatment efficacy. Over 35 million people in the U.S. lived with a chronic lung condition in 2023, as reported by the American Lung Association in September 2024, highlighting the need for these solutions. Such integration enables personalized adjustments and better patient-provider communication. For example, Adherium announced in April 2024 that its Hailie Smartinhaler received FDA clearance for AstraZeneca's Airsupra and Breztri inhalers, providing real-time medication usage insights. These advancements drive demand for technologically integrated therapeutics.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • GSK plc.
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca plc.
  • Boehringer Ingelheim International GmbH
  • Sanofi S.A.
  • Koninklijke Philips N.V.
  • Becton, Dickinson and Company
  • Sunovion Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Asthma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Asthma Therapeutics Market, By Drug Class:

  • Anti-inflammatory
  • Combination Therapy
  • Bronchodilators

Asthma Therapeutics Market, By Product:

  • Inhalers
  • Nebulizers

Asthma Therapeutics Market, By Route of Administration:

  • Oral
  • Inhaled
  • Others

Asthma Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Asthma Therapeutics Market.

Available Customizations:

Global Asthma Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Asthma Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Anti-inflammatory, Combination Therapy, Bronchodilators)
    • 5.2.2. By Product (Inhalers, Nebulizers)
    • 5.2.3. By Route of Administration (Oral, Inhaled, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Asthma Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Product
    • 6.2.3. By Route of Administration
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Asthma Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Route of Administration
    • 6.3.2. Canada Asthma Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Route of Administration
    • 6.3.3. Mexico Asthma Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Route of Administration

7. Europe Asthma Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Product
    • 7.2.3. By Route of Administration
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Asthma Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Route of Administration
    • 7.3.2. France Asthma Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Route of Administration
    • 7.3.3. United Kingdom Asthma Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Route of Administration
    • 7.3.4. Italy Asthma Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Route of Administration
    • 7.3.5. Spain Asthma Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Route of Administration

8. Asia Pacific Asthma Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Product
    • 8.2.3. By Route of Administration
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Asthma Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Route of Administration
    • 8.3.2. India Asthma Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Route of Administration
    • 8.3.3. Japan Asthma Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Route of Administration
    • 8.3.4. South Korea Asthma Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Route of Administration
    • 8.3.5. Australia Asthma Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Route of Administration

9. Middle East & Africa Asthma Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Product
    • 9.2.3. By Route of Administration
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Asthma Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Route of Administration
    • 9.3.2. UAE Asthma Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Route of Administration
    • 9.3.3. South Africa Asthma Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Route of Administration

10. South America Asthma Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Product
    • 10.2.3. By Route of Administration
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Asthma Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Route of Administration
    • 10.3.2. Colombia Asthma Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Route of Administration
    • 10.3.3. Argentina Asthma Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Asthma Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Teva Pharmaceutical Industries Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GSK plc.
  • 15.3. Merck & Co., Inc.
  • 15.4. F. Hoffmann-La Roche Ltd.
  • 15.5. AstraZeneca plc.
  • 15.6. Boehringer Ingelheim International GmbH
  • 15.7. Sanofi S.A.
  • 15.8. Koninklijke Philips N.V.
  • 15.9. Becton, Dickinson and Company
  • 15.10. Sunovion Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer